Boston Scientific Co. (NYSE:BSX) Shares Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 94.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,126 shares of the medical equipment provider’s stock after purchasing an additional 6,854 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Boston Scientific were worth $1,262,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Brooklyn FI LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $642,000. Xponance Inc. boosted its position in shares of Boston Scientific by 5.1% during the fourth quarter. Xponance Inc. now owns 219,139 shares of the medical equipment provider’s stock worth $19,573,000 after buying an additional 10,681 shares during the period. Intech Investment Management LLC raised its holdings in shares of Boston Scientific by 91.8% in the 4th quarter. Intech Investment Management LLC now owns 378,607 shares of the medical equipment provider’s stock valued at $33,817,000 after buying an additional 181,220 shares during the period. Generali Asset Management SPA SGR purchased a new position in Boston Scientific during the 4th quarter valued at about $10,749,000. Finally, Evoke Wealth LLC lifted its position in shares of Boston Scientific by 26.3% during the fourth quarter. Evoke Wealth LLC now owns 3,541 shares of the medical equipment provider’s stock worth $316,000 after purchasing an additional 738 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 1.6 %

Shares of NYSE BSX opened at $100.77 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm’s 50-day moving average is $101.45 and its two-hundred day moving average is $92.15. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a market capitalization of $148.72 billion, a PE ratio of 80.62, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Truist Financial raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Canaccord Genuity Group increased their target price on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a report on Monday, December 9th. UBS Group lifted their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Friday, January 10th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.